Menu

Filter articles published since 2015 by topic, disease, or article type.

Guidlines for filtering

Results are filtered to show all matching articles from a particular category, and to show only articles that match all selected categories.

For instance, if "Biomarkers" and "Genetics" are selected in the Topic category, and "Multiple sclerosis" is selected in the Disease category, all results that match EITHER the Biomarkers OR Genetics Topic category will be shown, but only if they also match the Multiple sclerosis Disease category; i.e. Boolean search of [("Biomarkers" OR "Genetics") AND "multiple sclerosis"]

Filter articles published since 2015 by topic, disease, or article type.

Guidlines for filtering

Results are filtered to show all matching articles from a particular category, and to show only articles that match all selected categories.

For instance, if "Biomarkers" and "Genetics" are selected in the Topic category, and "Multiple sclerosis" is selected in the Disease category, all results that match EITHER the Biomarkers OR Genetics Topic category will be shown, but only if they also match the Multiple sclerosis Disease category; i.e. Boolean search of [("Biomarkers" OR "Genetics") AND "multiple sclerosis"]

CQDM and ODE Co-Fund Collaboration to Identify Inhibitors of Protein Misfolding and Aggregation

The CQDM, a research consortium focused on precompetitive research to accelerate drug development, has partnered with the Ontario Center for Excellence (OCE) and together they have announced new funding for an industry-academic partnership to accelerate discovery of drugs that could be candidate therapies for neurodegenerative diseases, including ALS. The support will be granted to Xiao-Yan Wen of the Keenan Research Centre for Biomedical Sciences at St. Michael’s Hospital, Pierre Drapeau of the Université de Montréal and Chrisopher Barden from Treventis, to develop a high-throughput small molecule screening platform in zebrafish to accelerate screening and identification of compounds that inhibit protein misfolding and aggregation (to read more about use of the zebrafish model in ALS, see Aug 2013 news story). CQDM and OCE will each pitch in $150k and Treventis will add $600k to support this synergistic partnership.

The CQDM, a research consortium focused on precompetitive research to accelerate drug development, has partnered with the Ontario Center for Excellence (OCE) and together they have announced new funding for an industry-academic partnership to accelerate discovery of drugs that could be candidate therapies for neurodegenerative diseases, including ALS. The support will be granted to Xiao-Yan Wen of the Keenan Research Centre for Biomedical Sciences at St. Michael’s Hospital, Pierre Drapeau of the Université de Montréal and Chrisopher Barden from Treventis, to develop a high-throughput small molecule screening platform in zebrafish to accelerate screening and identification of compounds that inhibit protein misfolding and aggregation (to read more about use of the zebrafish model in ALS, see Aug 2013 news story). CQDM and OCE will each pitch in $150k and Treventis will add $600k to support this synergistic partnership.

Filter articles published since 2015 by topic, disease, or article type.

Guidlines for filtering

Results are filtered to show all matching articles from a particular category, and to show only articles that match all selected categories.

For instance, if "Biomarkers" and "Genetics" are selected in the Topic category, and "Multiple sclerosis" is selected in the Disease category, all results that match EITHER the Biomarkers OR Genetics Topic category will be shown, but only if they also match the Multiple sclerosis Disease category; i.e. Boolean search of [("Biomarkers" OR "Genetics") AND "multiple sclerosis"]